53Biologics
53Biologics is a Spanish biologics CDMO founded in 2017 that provides GMP manufacturing of monoclonal antibodies, recombinant proteins, and mRNA enzymes for global biopharmaceutical clients.
- Company typePrivate
- Founded2017
- HeadquartersLeón, Spain
- Headcount51–100
- GTM typeB2B
- OfferingServices
53Biologics firmographics
Firmographics- Name
- 53Biologics
- Website
- https://53biologics.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- 53Biologics is a Spanish biologics CDMO founded in 2017 that provides GMP manufacturing of monoclonal antibodies, recombinant proteins, and mRNA enzymes for global biopharmaceutical clients.
- Ownership category
- akta.pro rank
53Biologics industry classification
Industry- Product category
- Biologics Contract Manufacturing (CDMO)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industry
- mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)
Keywords
Where 53Biologics is headquartered
LocationHeadquarters
- HQ city
- León
- HQ country
- Spain
- HQ region
- Europe
Markets served
53Biologics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain
Revenue model
- Biologics Manufacturing Services: Contract development and manufacturing organization (CDMO) providing GMP production of monoclonal antibodies and recombinant proteins for biopharmaceutical clients. Revenue generated through service contracts for process development, manufacturing, and quality control.
Go-to-market motion1 record
Distribution channels1 record
53Biologics product offering
Product offeringCore offering
53Biologics is a Spanish Contract Development and Manufacturing Organization (CDMO) that provides GMP-certified biologics manufacturing services to global biopharmaceutical companies. Its core services cover process development, GMP production, and quality control of monoclonal antibodies and recombinant proteins, with additional specialized capabilities in manufacturing enzymes for messenger RNA (mRNA) therapeutics.
Differentiator
Problem solved
Functional benefit
Products and services
- GMP Monoclonal Antibody Manufacturing
Quantifiable outcome
- Expected to generate highly skilled jobs in engineering, quality control, and process development
Companies that use 53Biologics
Customer profileSegments2 records
Ideal customer profiles2 records
53Biologics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
53Biologics partnerships and signals
Strategic signalScale indicators3 records
53Biologics competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: Lonza is the world's largest biologics CDMO, offering GMP manufacturing for monoclonal antibodies, recombinant proteins, and cell/gene therapies. It is comparable to 53Biologics as a direct CDMO competitor serving overlapping biopharma customers, though at vastly greater scale across multiple global sites.
- Catalent: Catalent is a major global CDMO with biologics fill-finish, cell therapy, and gene therapy capabilities. It overlaps with 53Biologics in serving biopharma clients needing GMP biologics manufacturing, though at much larger scale and across multiple modalities.
- Samsung Biologics: Samsung Biologics is a top-tier global biologics CDMO providing large-scale contract manufacturing of monoclonal antibodies and recombinant proteins. It competes with 53Biologics for the same biopharma outsourcing customers but operates at enterprise scale with multi-plant capacity.
- WuXi Biologics: WuXi Biologics is one of the largest biologics CDMOs globally, offering end-to-end services for mAb and recombinant protein manufacturing. It is comparable to 53Biologics as a direct biologics CDMO competitor, though at vastly larger scale and global footprint.
- Boehringer Ingelheim BioXcellence: Boehringer Ingelheim BioXcellence is the biologics CDMO division of Boehringer Ingelheim, providing large-scale contract manufacturing for mAbs and recombinant proteins. It is a broad incumbent peer comparable to 53Biologics in serving the same biologics outsourcing market.
- Eurofins CDMO: Eurofins offers pharmaceutical and biopharmaceutical CDMO services including biologics testing and process development. It is comparable to 53Biologics as a broader CDMO incumbent serving European biopharma with overlapping GMP-related services.
Direct peers
- AGC Biologics: AGC Biologics is a mid-to-large global CDMO specializing in GMP production of monoclonal antibodies, recombinant proteins, and viral vectors. It is a direct competitor to 53Biologics in the mammalian-cell biologics CDMO space and serves similar biotech and biopharma customers.
- Rentschler Biologics: Rentschler Biologics is a European-based CDMO specialized in mammalian cell-based GMP production of mAbs and recombinant proteins. It is a direct peer to 53Biologics serving the same European biopharma market with a closely aligned technology and customer overlap.
- Mabxience: Mabxience is an Argentinian-Spanish biosimilars developer and CDMO with mAb manufacturing capabilities. It is a direct head-to-head competitor to 53Biologics in the Spanish/Iberian biologics CDMO market, particularly in mAb manufacturing for clinical and commercial supply.
Emerging players
- Polypeptide Group: Polypeptide Group is a specialized CDMO focused on peptide and oligonucleotide manufacturing. While smaller scale and different modality, it overlaps with 53Biologics as a European CDMO serving similar therapeutic developers requiring outsourced GMP manufacturing.
Market position
Customer concentration
53Biologics social profiles
Digital presence53Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
53Biologics leadership team
Management profileNumber of profiles
Profiles1 record
53Biologics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
53Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 53Biologics
What does 53Biologics do?
53Biologics is a Spanish Contract Development and Manufacturing Organization (CDMO) that provides GMP-certified biologics manufacturing services to global biopharmaceutical companies. Its core services cover process development, GMP production, and quality control of monoclonal antibodies and recombinant proteins, with additional specialized capabilities in manufacturing enzymes for messenger RNA (mRNA) therapeutics.
Is 53Biologics a public or private company?
53Biologics is a private company. It is classified as venture growth investor backed and is currently operating.
When was 53Biologics founded?
53Biologics was founded in 2017. It employs 51 to 100 people.
Where is 53Biologics based?
53Biologics is headquartered in León, Spain, in the Europe region.
How does 53Biologics make money?
One revenue line is on record: biologics Manufacturing Services.
Who are 53Biologics's main competitors?
Broad incumbents on record are Lonza Group, Catalent, Samsung Biologics, WuXi Biologics, Boehringer Ingelheim BioXcellence and Eurofins CDMO. Direct peers are AGC Biologics, Rentschler Biologics and Mabxience. Polypeptide Group is listed as an emerging player.
Does 53Biologics have an API?
No public API is recorded for 53Biologics.
What industry is 53Biologics in?
53Biologics's product category is Biologics Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO. Its NAICS code is 325414 and its SIC code is 2836.